AT204299T - Human monoclonal anti-tnf alpha antibody - Google Patents

Human monoclonal anti-tnf alpha antibody

Info

Publication number
AT204299T
AT204299T AT94102560T AT94102560T AT204299T AT 204299 T AT204299 T AT 204299T AT 94102560 T AT94102560 T AT 94102560T AT 94102560 T AT94102560 T AT 94102560T AT 204299 T AT204299 T AT 204299T
Authority
AT
Austria
Prior art keywords
human monoclonal
monoclonal anti
tnf alpha
alpha antibody
antibody
Prior art date
Application number
AT94102560T
Other languages
German (de)
Inventor
Petra Boyle
Gayle D Wetzel
Kenneth J Lembach
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to US2695793A priority Critical
Priority to US14506093A priority
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of AT204299T publication Critical patent/AT204299T/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26701860&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AT204299(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241Tumor Necrosis Factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
AT94102560T 1993-03-05 1994-02-21 Human monoclonal anti-tnf alpha antibody AT204299T (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US2695793A true 1993-03-05 1993-03-05
US14506093A true 1993-10-29 1993-10-29

Publications (1)

Publication Number Publication Date
AT204299T true AT204299T (en) 2001-09-15

Family

ID=26701860

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94102560T AT204299T (en) 1993-03-05 1994-02-21 Human monoclonal anti-tnf alpha antibody

Country Status (11)

Country Link
US (1) US5654407A (en)
EP (1) EP0614984B2 (en)
JP (2) JP4225519B2 (en)
AT (1) AT204299T (en)
CA (1) CA2116888C (en)
DE (3) DE122009000074I1 (en)
DK (1) DK0614984T4 (en)
ES (1) ES2159529T5 (en)
LU (1) LU91661I2 (en)
NL (1) NL300421I2 (en)
PT (1) PT614984E (en)

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672347A (en) * 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
IL73883A (en) * 1984-12-20 1990-12-23 Yeda Res & Dev Monoclonal antibodies against tnf-alpha,hybridomas producing them and method for the purification of tnf-alpha
US20030225254A1 (en) * 1989-08-07 2003-12-04 Rathjen Deborah Ann Tumour necrosis factor binding ligands
US5959087A (en) * 1989-08-07 1999-09-28 Peptide Technology, Ltd. Tumour necrosis factor binding ligands
WO1991002078A1 (en) 1989-08-07 1991-02-21 Peptide Technology Ltd Tumour necrosis factor binding ligands
US6713610B1 (en) * 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US6277969B1 (en) * 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US20110195063A1 (en) * 2000-08-07 2011-08-11 Centocor, Inc. Methods of Treating Ankylosing Spondylitis Using Anti-TNF Antibodies and Peptides of Human Tumor Necrosis Factor
US20050249735A1 (en) * 2000-08-07 2005-11-10 Centocor, Inc. Methods of treating ankylosing spondylitis using anti-TNF antibodies and peptides of human tumor necrosis factor
US20050260201A1 (en) * 1993-01-29 2005-11-24 Centocor, Inc. Methods of treating rheumatoid arthritis using anti-TNF receptor fusion proteins
US20060018907A1 (en) * 2000-08-07 2006-01-26 Centocor, Inc. Anti-TNF antibodies and peptides of human tumor necrosis factor
GB9109645D0 (en) * 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
RU2270030C2 (en) * 1996-02-09 2006-02-20 Абботт Байотекнолоджи эЛтиди. METHOD AND OBTAINED HUMAN ANTIBODY OR ITS ANTIGEN-BINDING FRAGMENT FOR INHIBITING HUMAN TNFα ACTIVITY, APPLYING THE OBTAINED HUMAN ANTIBODY OR ITS ANTIGEN-BINDING FRAGMENT AS INGREDIENT FOR PRODUCING MEDICAMENT
AU2013257402B2 (en) * 1996-02-09 2014-02-20 Abbvie Biotechnology Ltd Human antibodies that bind human TNFalpha
AU2012261708B2 (en) * 1996-02-09 2014-02-20 Abbvie Biotechnology Ltd Human antibodies that bind human TNFalpha
AU2013203420B2 (en) * 1996-02-09 2014-02-20 Abbvie Biotechnology Ltd Human antibodies that bind human TNFalpha
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
EP2314625B1 (en) * 1996-12-03 2014-05-07 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
US6395273B1 (en) * 1998-06-10 2002-05-28 Promega Corporation Prevention and treatment of inflammatory bowel disease
US7494652B1 (en) 1998-06-10 2009-02-24 Promega Corporation Treatment of sepsis
PT1107996E (en) * 1998-08-28 2002-10-31 Genentech Inc Anti-factor ix / ixa human antibodies
WO2000051637A1 (en) * 1999-03-02 2000-09-08 Centocor, Inc. ANTI-TNFα ANTIBODIES IN THERAPY OF ASTHMA
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
NZ519222A (en) * 1999-12-14 2004-04-30 Genentech Inc TNF-alpha antagonists and LFA-1 antagonist for treating LFA-1 or TNF-alpha mediated disorder
TWI327597B (en) 2001-08-01 2010-07-21 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
US7250165B2 (en) * 2000-08-07 2007-07-31 Centocor, Inc. Anti-TNF antibodies, compositions, methods and uses
US20090081234A1 (en) * 2000-08-07 2009-03-26 George Heavner Anti-tnf antibodies, compositions, methods and uses for treatment of depression and related conditions
US20040120952A1 (en) * 2000-08-07 2004-06-24 Centocor, Inc Anti-TNF antibodies and peptides of human tumor necrosis factor
CA2868614A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
ES2675735T3 (en) 2001-06-26 2018-07-12 Amgen Inc. OPGL antibodies
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US20040009172A1 (en) * 2002-04-26 2004-01-15 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
CA2880296A1 (en) * 2002-07-19 2004-01-29 Abbvie Biotechnology Ltd. Treatment of tnf.alpha. related disorders
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
WO2004019861A2 (en) * 2002-08-28 2004-03-11 Pharmacia Corporation Stable ph optimized formulation of a modified antibody
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
NZ540195A (en) 2002-11-08 2009-01-31 Ablynx Nv Stabilized single domain antibodies
US20060034845A1 (en) 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
JP4754219B2 (en) 2002-12-02 2011-08-24 アムジエン・フレモント・インコーポレイテツド Antibodies directed against tumor necrosis factor and their use
EP1578782A4 (en) 2002-12-30 2007-09-12 Amgen Inc Combination therapy with co-stimulatory factors
US7101978B2 (en) * 2003-01-08 2006-09-05 Applied Molecular Evolution TNF-α binding molecules
US7435799B2 (en) * 2004-01-08 2008-10-14 Applied Molecular Evolution TNF-α binding molecules
US20040185047A1 (en) * 2003-03-21 2004-09-23 Jill Giles-Komar Anti- TNF antibodies, compositions, methods and uses
EP1460088A1 (en) * 2003-03-21 2004-09-22 Biotest AG Humanized anti-CD4 antibody with immunosuppressive properties
TWI556829B (en) 2004-04-09 2016-11-11 Abbvie Biotechnology Ltd Multiple variable dose therapy for the treatment of TNFα-related disorders
JP2008505654A (en) * 2004-07-12 2008-02-28 ラパポート・ファミリー・インスティテュート・フォー・リサーチ・イン・ザ・メディカル・サイエンシーズRappaport Family Institute for Research in the Medical Sciences A method for detecting the phenotype of the polymorphic protein
US20060083741A1 (en) * 2004-10-08 2006-04-20 Hoffman Rebecca S Treatment of respiratory syncytial virus (RSV) infection
JP4642862B2 (en) * 2004-12-29 2011-03-02 ユーハン・コーポレイションYUHAN Corporation Humanized antibody specific for human tumor necrosis factor-alpha
US8715664B2 (en) 2005-05-16 2014-05-06 Abbvie Biotechnology Ltd. Use of human TNFα antibodies for treatment of erosive polyarthritis
US8067547B2 (en) 2005-06-07 2011-11-29 ESBATech, an Alcon Biomedical Research Unit, LLC Stable and soluble antibodies inhibiting TNFα
EP1915620B1 (en) * 2005-08-02 2010-06-02 Xbiotech Inc DIAGNOSIS, TREATMENT, AND PREVENTION OF VASCULAR DISORDERS USING IL-1alpha AUTOANTIBODIES
US20070041905A1 (en) * 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
AU2006291990B2 (en) * 2005-09-13 2012-05-31 National Research Council Of Canada Methods and compositions for modulating tumor cell activity
JP4861019B2 (en) * 2006-01-31 2012-01-25 独立行政法人科学技術振興機構 Antibody enzyme against human TNF-α and use thereof
EP2738178A1 (en) 2006-04-05 2014-06-04 AbbVie Biotechnology Ltd Antibody purification
US20090317399A1 (en) * 2006-04-10 2009-12-24 Pollack Paul F Uses and compositions for treatment of CROHN'S disease
WO2007120656A2 (en) 2006-04-10 2007-10-25 Abbott Biotechnology Ltd. Uses and compositions for treatment of rheumatoid arthritis
US20080118496A1 (en) * 2006-04-10 2008-05-22 Medich John R Uses and compositions for treatment of juvenile rheumatoid arthritis
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
EP2007426A4 (en) 2006-04-10 2010-06-16 Abbott Biotech Ltd Uses and compositions for treatment of psoriatic arthritis
US20080131374A1 (en) * 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
US20110008282A1 (en) * 2006-05-15 2011-01-13 Xbiotech, Inc. IL-1alpha immunization induces autoantibodies protective against atherosclerosis
CN101472948A (en) * 2006-05-22 2009-07-01 埃克斯生物科技公司 Treatment of cancer with anti-IL-1alpha antibodies
KR20090100461A (en) * 2007-01-16 2009-09-23 아보트 러보러터리즈 Methods for treating psoriasis
CA2683801A1 (en) * 2007-06-06 2008-12-11 Domantis Limited Polypeptides, antibody variable domains and antagonists
US8999337B2 (en) 2007-06-11 2015-04-07 Abbvie Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis by inhibition of TNFα
US20090038182A1 (en) * 2007-08-09 2009-02-12 Lans Maris J Footwear with built-in scale
CA2696210A1 (en) 2007-08-28 2009-03-12 Abbott Biotechnology Ltd. Compositions and methods comprising binding proteins for adalimumab
EP2249809A1 (en) 2008-01-15 2010-11-17 Abbott GmbH & Co. KG Powdered protein compositions and methods of making same
WO2009097095A2 (en) * 2008-01-28 2009-08-06 The Regents Of The University Of California Methods for treating hematopoietic malignancies
EP2262838B1 (en) * 2008-03-13 2016-04-13 Biotest AG Agent for treating disease
RU2531548C2 (en) * 2008-09-29 2014-10-20 Биотест Аг Composition for treating disease
BRPI0909048A2 (en) * 2008-03-13 2015-11-24 Biotest Ag pharmaceutical composition and method of treating an autoimmune disease
SG190627A1 (en) * 2008-03-13 2013-06-28 Biotest Ag Agent for treating disease
CA2717569A1 (en) 2008-03-18 2009-09-24 Abbott Laboratories Methods for treating psoriasis
CA2726345C (en) * 2008-05-30 2018-08-28 Xbiotech, Inc. Interleukin-1 alpha antibodies and methods of use
KR101893010B1 (en) 2008-06-25 2018-08-29 에스바테크 - 어 노바티스 컴파니 엘엘씨 STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα
CN102209557A (en) * 2008-09-12 2011-10-05 埃克斯生物科技公司 Targeting pathogenic monocytes
US8415291B2 (en) * 2008-10-31 2013-04-09 Centocor Ortho Biotech Inc. Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
CA2742791A1 (en) * 2008-11-28 2010-06-03 Abbott Laboratories Stable antibody compositions and methods for stabilizing same
US8349325B2 (en) 2008-12-23 2013-01-08 Abbott Laboratories Soluble FMS-like tyrosine kinase-1 (sFLT-1) antibody and related composition, kit, methods of using, and materials and method for making
RU2012114854A (en) * 2009-09-14 2013-10-27 Эбботт Лэборетриз Methods for treating psoriasis
CA2928846A1 (en) 2009-11-24 2011-06-03 Alethia Biotherapeutics Inc. Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume
GB0920944D0 (en) 2009-11-30 2010-01-13 Biotest Ag Agents for treating disease
CA2787755A1 (en) 2010-01-20 2011-07-28 Tolerx, Inc. Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments
US9023997B2 (en) 2010-01-20 2015-05-05 Merck Sharp & Dohme Corp. Anti-ILT5 antibodies and ILT5-binding antibody fragments
CN102167741B (en) * 2010-02-25 2014-05-14 上海百迈博制药有限公司 Fully human anti-TNF-alpha (Tumor Necrosis Factor-alpha) monoclonal antibody and preparation method as well as application thereof
US20110229921A1 (en) 2010-03-18 2011-09-22 Abbott Laboratories METHODS OF ASSAYING URINARY NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN (uNGAL) IN THE PROGNOSIS OF CADAVERIC KIDNEY TRANSPLANT FUNCTION IN A PATIENT, INCLUDING A PATIENT DIAGNOSED WITH DELAYED GRAFT FUNCTION (DGF), A METHOD OF ASSAYING uNGAL IN THE ASSESSMENT OF RISK OF DGF IN A PATIENT DIAGNOSED WITH EARLY GRAFT FUNCTION (EGF), AND RELATED KITS
WO2011163558A1 (en) 2010-06-25 2011-12-29 Abbott Laboratories Materials and methods for assay of anti-hepatitis c virus (hcv) antibodies
DK2608808T3 (en) 2010-08-23 2017-04-24 Xbiotech Inc Treatment of neoplastic diseases
US20120115244A1 (en) 2010-11-09 2012-05-10 Abbott Laboratories Materials and methods for immunoassay of pterins
CN102539778A (en) * 2010-12-24 2012-07-04 北京义翘神州生物技术有限公司 Enzyme linked immunosorbent assay kit for detecting recombinant human tumor necrosis factor-alpha
US20140051586A1 (en) * 2011-01-25 2014-02-20 Ignacio Pino High-throughput methods to produce, validate and characterize mmabs
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
WO2013043973A2 (en) 2011-09-23 2013-03-28 Xbiotech, Inc. Cachexia treatment
US8993248B2 (en) 2011-12-31 2015-03-31 Abbott Laboratories Truncated human vitamin D binding protein and mutation and fusion thereof and related materials and methods of use
EA201491568A1 (en) 2012-02-22 2014-11-28 Алетиа Байотерапьютикс Инк. Joint application of clusterin inhibitor and egfr inhibitor for cancer treatment
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
AU2013309506A1 (en) 2012-09-02 2015-03-12 Abbvie Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
EP2830651A4 (en) 2013-03-12 2015-09-02 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
EP2968550B1 (en) 2013-03-14 2018-11-14 Ffe Therapeutics LLC Compositions and methods for treating angiogenesis-related disorders
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989000607A1 (en) 1987-07-09 1989-01-26 The United States Of America, As Represented By Th Preparation of human monoclonal antibodies of selected specificity and isotypes
EP0487610B1 (en) * 1989-08-16 2000-02-09 Chiron Corporation Prohormone cleavage site blocking antibody
GB8921123D0 (en) * 1989-09-19 1989-11-08 Millar Ann B Treatment of ards
GB9109645D0 (en) 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
DK0585705T3 (en) 1992-08-28 1999-07-26 Bayer Ag The use of monoclonal anti-TNF antibodies for the treatment of bacterial meningitis

Also Published As

Publication number Publication date
CA2116888C (en) 2003-08-12
DE69427928D1 (en) 2001-09-20
DK614984T4 (en)
JPH06319587A (en) 1994-11-22
EP0614984A3 (en) 1995-05-24
DE69427928T3 (en) 2012-05-10
LU91661I2 (en) 2010-05-10
NL300421I1 (en) 2010-01-04
CA2116888A1 (en) 1994-09-06
JP2009046487A (en) 2009-03-05
PT614984E (en) 2001-12-28
DK0614984T3 (en) 2001-11-05
JP4225519B2 (en) 2009-02-18
ES2159529T3 (en) 2001-10-16
EP0614984B1 (en) 2001-08-16
EP0614984A2 (en) 1994-09-14
US5654407A (en) 1997-08-05
DK0614984T4 (en) 2010-12-20
EP0614984B2 (en) 2010-11-03
DK614984T3 (en)
LU91661A9 (en)
DE122009000074I1 (en) 2011-12-01
NL300421I2 (en) 2010-04-01
ES2159529T5 (en) 2011-03-09
DE69427928T2 (en) 2001-11-29

Similar Documents

Publication Publication Date Title
DE69232137T2 (en) Multivalent antigen-binding proteins
DE69221147D1 (en) Not glycosylated anti-CD3 IgG antibodies
DE69233051D1 (en) Antibodies against CD40-L
DE69133095T2 (en) Cyclosporine immunoassay
DE69327229D1 (en) Multivalent single chain antibodies
DE69430818T2 (en) Pns-dns-pns chimeric macromolecules
DK0809656T3 (en) Monoclonal antibodies specific for beta-A4 peptide
DE69609604T2 (en) cementing
DE69838062D1 (en) Human monoclonal antibody directed against the epidermal growth factor receptor
DE69220503T2 (en) Monoclonal antibodies against the protein tau mikrotubulusassoziierte.
DK0773228T3 (en) A process for the preparation of human monoclonal antibodies and their use
DK0504363T4 (en) Purified IgG antibodies
EE201200006A (en) Anti-CTLA-4 human monoclonal antibodies
EE200100336A (en) Anti-CTLA-4 human monoclonal antibodies
DE69829891D1 (en) Anti-VEGF antibody
NO950881L (en) Neutralizes human monoclonal antibodies against respiratory syncytial virus
NO2009021I1 (en) protein D
DE69231828D1 (en) For human tumor necrosis factor-specific monoclonal and chimeric antibodies
NL300238I2 (en) Humanized antibodies against VLA-4 leukocytenadhesiemolecule
NO963475D0 (en) Antibody purification
DE69133472D1 (en) Antibodies and their therapeutic use
BR9608884A (en) Human monoclonal antibodies specific high affinity for RSV F protein
DE122004000008I1 (en) Humanized antibodies heregulin.
DE69422523D1 (en) Anti-gp39 antibodies and their uses
DE69329643T2 (en) Against carcinoma-associated antigenic antibodies directed

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
ESZA Application filed for a certificate of protection (e-series)

Free format text: SZ 45/2009, 20091111

Spc suppl protection certif: SZ 45/2009

Filing date: 20091111

UEP Publication of translation of european patent specification

Ref document number: 0614984

Country of ref document: EP